Posology : מינונים

4.2   Posology and method of administration
Imitrex Nasal Spray should not be used prophylactically.
The recommended dose of Imitrex Nasal Spary should not be exceeded.

Imitrex Nasal Spray is recommended as monotherapy for the acute treatment of a migraine attack and should not be given concomitantly with ergotamine or derivatives of ergotamine (including methysergide) (see section 4.3).
It is advisable that Imitrex Nasal Spray be given as early as possible after the onset of a migraine headache. It is equally effective at whatever stage of the attack it is administered.
Adults (18 years of age and over)
The optimal dose of Imitrex Nasal Spray is 20 mg for administration into one nostril.
If a patient does not respond to the first dose of Imitrex Nasal Spray, a second dose should not be taken for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid or non-steroidal anti-inflammatory drugs. Imitrex Nasal Spray may be taken for subsequent attacks.
If the patient has responded to the first dose but the symptoms recur, a second dose may be given in the following 24 hours, provided that there is a minimum interval of 2 hours between the two doses.
No more than two doses of 20 mg Nasal Spray should be taken in any 24-hour period.
Children (under 18 years of age)
The use of Imitrex Nasal Spray 20 mg is not recommended in patients under the age of 18 years.
Elderly (over 65)
There is no experience of the use of Imitrex Nasal Spray in patients over 65. The pharmacokinetics in elderly patients have not been sufficiently studied. Therefore the use of sumatriptan is not recommended until further data are available.